Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GE Healthcare

National Institute for Health and Care Excellence NICE logo

UK backs use of drugs to prevent breast cancer

Daily use of tamoxifen or raloxifene recommended in at-risk women

- PMLiVE

Astellas wins EU approval for prostate cancer drug Xtandi

Will compete with J&J’s big-selling Zytiga

- PMLiVE

Cost deters NICE from Sanofi’s bowel cancer drug Zaltrap

Fails to win recommendation despite patient access scheme

GE Healthcare plans $2bn software investment

Will focus on the convergence of machine and intelligent data

- PMLiVE

Sanofi and AstraZeneca form cancer research alliances with non-profits

Will work respectively with Curie Institute in France and Cancer Research UK

- PMLiVE

J&J acquires oncology candidate in $1bn Aragon buy

ARN-509 is in phase II development for castration resistant prostate cancer

- PMLiVE

Men’s oesophageal cancer risk “triple that of women”

New data from Cancer Research UK shines slight on 'quiet epidemic'

- PMLiVE

Roche’s Avastin gains Japanese approval for brain cancer

Marks drug's first approval to treat newly diagnosed glioblastoma

- PMLiVE

Electronic medical records ‘could boost clinical trial efficiency’

Quicker recruitment times and lower development costs among potential benefits, says Parexel

- PMLiVE

FDA turns down tivozanib for kidney cancer

Agency describes data provided by Aveo Oncology and Astellas as "uninterpretable"

Roche - Basel

EU approves new use of Roche’s RoActemra in children

Swiss pharma firm hopes to increase revenue from arthritis drug to tip it into blockbuster status

- PMLiVE

Data control: pharma and big data in healthcare

Whether it's big, smart or right, this could be the year pharma and healthcare sees large benefits from data

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links